Gene therapy and vein graft patency in coronary artery bypass graft surgery

JAMA

Volumn 294, Issue 19, 2005, Pages 2495-2497

  Conti, Vincent R ^a   Hunter, Glenn C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; TRANSCRIPTION FACTOR E2F;

ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DNA MICROARRAY; DRUG EFFECT; EDITORIAL; ENDOTHELIUM INJURY; GENE CONTROL; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GRAFT FAILURE; HEMODYNAMIC MONITORING; HUMAN; HYPERPLASIA; INJURY; ISCHEMIA; MAMMARY ARTERY; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE; THROMBOSIS; VASCULAR LESION; VEIN GRAFT;

EID: 27744560921     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.19.2495     Document Type: Editorial

References (23)

1. Perrault LP, Jeanmart H, Bilodeau L, et al. Early quantitative coronary angiography of saphenous vein grafts for coronary artery bypass grafting harvested by means of open versus endoscopic saphenectomy: a prospective randomized trial. J Thorac Cardiovasc Surg. 2004;127:1402-1407.
2. Yun KL, Wu Y, Aharonian V, et al. Randomized trial of endoscopic versus open vein harvest for coronary artery bypass grafting: six-month patency rates. J Thorac Cardiovasc Surg. 2005;129:496-503.
3. Cataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E. Factors influencing 1-year patency of coronary artery saphenous vein grafts. Circulation. 1993;88:II93-II98.
4. Lesperance J, Bourassa MG, Biron P, Campeau L, Saltiel J. Aorta to coronary artery saphenous vein grafts: preoperative angiographic criteria for successful surgery. Am J Cardiol. 1972;30:459-465.
5. Lie JT, Lawrie GM, Morris GC Jr. Aortocoronary bypass saphenous vein graft atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol. 1977;40:906-914.
6. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
7. Campeau L, Hunninghake DB, Knatterud GL, et al; Post CABG Trial Investigators. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical trial. Circulation. 1999;99:3241-3247.
8. Barboriak JJ, Pintar K, Van Horn DL, Batayias GE, Korns ME. Pathologic findings in the aortocoronary vein grafts: a scanning electron microscope study. Atherosclerosis. 1978;29:69-80.
9. Fuster V, Chesebro JJ. Aortocoronary artery vein-graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. Circulation. 1985;72:V65-V70.
10. Bulkley BH, Hutchins GM. Accelerated "atherosclerosis": a morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation. 1977;55:163-169.
11. Schwartz SM. Perspectives series: cell adhesion in vascular biology: smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997;99:2814-2816.
12. Shuhaiber JH, Evans AN, Massad MG, Geha AS. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg. 2002;22:387-396.
13. Hilker M, Langin T, Hake U, et al. Gene expression profiling of human stenotic aorto-coronary bypass grafts by cDNA array analysis. Eur J Cardiothorac Surg. 2003;23:620-625.
14. Maiti B, Li J, de Bruin A, et al. Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 2005;280:18211-18220.
15. Giangrande PH, Zhu W, Schlisio S, et al. A role for E2F6 in distinguishing G1/S-and G2/M-specific transcription. Genes Dev. 2004;18:2941-2951.
16. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg. 2001;121:714-722.
17. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493-1498.
18. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
19. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446-2454.
20. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-626.
21. Desai ND, Cohen EA, Naylor CD, Fremes SE. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351:2302-2309.
22. Manninen HI, Jaakkola P, Suhonen M, Rehnberg S, Vuorenniemi R, Matsi PJ. Angiographic predictors of graft patency and disease progression after coronary artery bypass grafting with arterial and venous grafts. Ann Thorac Surg. 1998;66:1289-1294.
23. Widimsky P, Straka Z, Stros P, et al. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation. 2004;110:3418-3423.